Coronary/Structural Heart

Medtronic HeartWare(TM) HVAD(TM) System Approved for Destination Therapy

DUBLIN – September 27, 2017 – Medtronic plc (NYSE: MDT) has received U.S. Food and Drug Administration (FDA) approval for its HeartWare(TM) HVAD(TM) System as a destination therapy for patients with advanced heart failure who are not candidates for heart transplants. The HVAD System, a left ventricular assist device or LVAD, […]

Abiomed (ABMD) Gets in on Magenta Medical’s $15 Million Funding Round

TEL-AVIV, Israel, September 28, 2017 /PRNewswire/ — Magenta Medical, a medical device company in the field of transcatheter heart failure therapy, announced today the successful closing of its $15M series B financing round. The syndicate of investors is comprised of Abiomed Inc., a leader in transcatheter heart pumps, Pitango Venture Capital, among Israel’s leading venture capital […]

Analytics 4 Life Raises $25 Million in Series B Financing to Advance its Artificial Intelligence-Backed Cardiac Imaging Technology

RESEARCH TRIANGLE PARK, NC and TORONTO, CANADA, September 27, 2017 — Analytics 4 Life, a digital health company applying the power of artificial intelligence to develop solutions that improve existing care pathways, today announced it has completed a $25 million Series B financing. This unique financing event was supported by an […]

Corindus Announces Opening of First International Robotic Training Center

WALTHAM, Mass.–(BUSINESS WIRE)–Corindus Vascular Robotics, Inc. [NYSE American: CVRS], a leading developer of precision vascular robotics, announced today the opening of the first international CorPath GRX Robotic Center in Tokyo, Japan. Earlier this year, Corindus partnered with Japan Medicalnext Co., Ltd., a wholly-owned entity of MC Healthcare, Inc. (subsidiary of […]

BioCardia Announces Successful Interim Safety Analysis In Its Phase III Clinical Trial Of Cardiamp Stem Cell Therapy For Heart Failure

SAN CARLOS, Calif.–(BUSINESS WIRE)–BioCardia (OTC: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced that the independent Data Safety Monitoring Board (DSMB) has completed the pre-specified interim analysis of safety outcomes for the first 10 patients treated in the Phase 3 trial of its […]

How Stopping Aspirin Can Increase Risk of Cardiac Event by Almost 40%

By Ken Dropiewski, Prime-Core Executive Search (ken@prime-core.com) An aspirin a day has been a standard recommendation for those diagnosed with certain types of coronary disease for decades. However, knowing patients like we do, medication non-compliance is a real problem -especially when it comes to recommended non-prescription drugs. So, what happens […]

Reflow Medical Announces 510(k) Clearance to Market Wingman Crossing Catheter for Coronary Indication

SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Reflow Medical, Inc., a developer and innovator of crossing and support catheters for use in the treatment of occlusive cardiovascular disease, announced that the company has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its Wingman14C Crossing Catheter for use in conjunction […]

TherOx Announces Its PMA Application for AMI Therapy System is Accepted for Filing by FDA

IRVINE, Calif.–(BUSINESS WIRE)–TherOx, Inc., a privately held medical device company focused on improving treatment of Acute Myocardial Infarction (AMI), announced that the U.S. Food and Drug Administration (FDA) has accepted the Premarket Approval (PMA) application for its Supersaturated Oxygen (SSO2) Therapy system. The second-generation SSO2 Therapy system is designed to reduce […]

BioStable Science & Engineering Announces the First Commercial Use of the HAART 200™ Aortic Annuloplasty Device

AUSTIN, Texas–(BUSINESS WIRE)–BioStable Science & Engineering, Inc. announced today the first commercial use of the HAART 200 Aortic Annuloplasty Device in the U.S. by doctors at the West Virginia University (WVU) Heart and Vascular Institute in Morgantown, West Virginia. Drs. Lawrence Wei, Vinay Badhwar and J. Scott Rankin were the […]

W. L. Gore & Associates Completes Patient Enrollment In U.S. Pivotal Clinical Study Of GORE CARDIOFORM ASD Occluder

FLAGSTAFF, Ariz.–(BUSINESS WIRE)–W. L. Gore & Associates, Inc. (Gore) has completed enrollment for the pivotal phase of the Gore ASSURED Clinical Study. This investigational device exemption (IDE) trial is researching the new GORE®CARDIOFORM ASD Occluder for the interventional closure of Atrial Septal Defects (ASDs), sized 8 to 35 mm. The […]